Myelodysplastic Syndromes Clinical Trials in Houston, Texas

19 studies are recruiting for myelodysplastic syndromes in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

    This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson, Houston, Texas
    Locations
    32 in total
    Run by
    Disc Medicine, Inc

    See if you can join NCT05320198 on ClinicalTrials.gov

  2. A Study of BGB-11417 in Participants With Myeloid Malignancies

    The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Md Anderson Cancer Center, Houston, Texas
    Locations
    47 in total
    Run by
    BeOne Medicines

    See if you can join NCT04771130 on ClinicalTrials.gov

  3. A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

    To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    2 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT06566742 on ClinicalTrials.gov

  4. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

    The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Univ of Texas MD Anderson Cancer Center, Division of Cancer Medicine, Houston, Texas
    Locations
    53 in total
    Run by
    Takeda

    See if you can join NCT04419649 on ClinicalTrials.gov

  5. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

    The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also chec…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    U.T. MD Anderson Cancer Center, Division of Cancer Medicine, Houston, Texas
    Locations
    177 in total
    Run by
    Takeda

    See if you can join NCT06499285 on ClinicalTrials.gov

  6. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

    Stage
    Phase 1
    Ages
    12 to 78
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    12 in total
    Run by
    Orca Biosystems, Inc.

    See if you can join NCT03802695 on ClinicalTrials.gov

  7. Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

    The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will re…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    30 in total
    Run by
    Institut de Recherches Internationales Servier

    See if you can join NCT02074839 on ClinicalTrials.gov

  8. A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

    To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT05365035 on ClinicalTrials.gov

  9. A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

    The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    GSK Investigational Site, Houston, Texas
    Locations
    39 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT06847867 on ClinicalTrials.gov

  10. Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

    This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with severe renal impairment and cance…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson, Houston, Texas
    Locations
    21 in total
    Run by
    Taiho Oncology, Inc.

    See if you can join NCT04953897 on ClinicalTrials.gov

  11. Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

    This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with moderate and se…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson, Houston, Texas
    Locations
    22 in total
    Run by
    Taiho Oncology, Inc.

    See if you can join NCT04953910 on ClinicalTrials.gov

  12. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    71 in total
    Run by
    Taiho Oncology, Inc.

    See if you can join NCT04256317 on ClinicalTrials.gov

  13. A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

    The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic sy…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas MD Anderson Cancer Center, Houston, Texas
    Locations
    8 in total
    Run by
    Chordia Therapeutics, Inc.

    See if you can join NCT05732103 on ClinicalTrials.gov

  14. A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

    Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). Th…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Texas M. D. Anderson Cancer Center, Houston, Texas
    Locations
    8 in total
    Run by
    GluBio Therapeutics Inc.

    See if you can join NCT06146257 on ClinicalTrials.gov

  15. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage
    Phase 1
    Ages
    12 and older
    Site
    MDACC, Houston, Texas
    Locations
    104 in total
    Run by
    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov

  16. Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

    This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD

    Stage
    Phase 1
    Ages
    18 and older
    Site
    M.D. Anderson Cancer Center, Department of Leukemia, Houston, Texas
    Locations
    2 in total
    Run by
    Montefiore Medical Center

    See if you can join NCT05986240 on ClinicalTrials.gov

  17. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Houston, Texas
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  18. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

    Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The University of Texas M.D. Anderson Cancer Center, Houston, Texas
    Locations
    13 in total
    Run by
    BlossomHill Therapeutics

    See if you can join NCT06501196 on ClinicalTrials.gov

  19. Study of REM-422 in Patients With AML or Higher Risk MDS

    The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    9 in total
    Run by
    Remix Therapeutics

    See if you can join NCT06297941 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.